Abstract
Salivary gland tumors are a highly heterogeneous group that accounts for 3 to 6% of all head and neck neoplasias, with an incidence ranging from 0.4 to 13.5 cases/100,000 individuals. Due to their clinic pathologic variability, the diagnosis of these tumors becomes a real challenge even for experiment pathologists, which avoid the identification of biomarkers with effective clinical relev…